<p>Lisanti Capital Growth LLC 在第二季度削減了其在 Apellis Pharmaceuticals, Inc.（NASDAQ:APLS - Free Report）的持股，根據該公司最新向 SEC 提交的 Form 13F 文件，該基金在本季度出售了 64325 股，持有公司股票 24885 股。Lisanti Capital Growth LLC 在最新報告期結束時持有的 Apellis Pharmaceuticals 股票價值 95.5 萬美元。</p>
<ul>
<li>Beam Therapeutics 因基因療法許可支付而大幅上漲</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也增加或減少了對 APLS 的持股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第四季度增加了對 Apellis Pharmaceuticals 股票的持股比例，增長了 2.8%。查爾斯·施瓦布投資管理公司現在擁有公司股票 904409 股，價值 5413.8 萬美元，在此期間購買了 25052 股。挪威中央銀行在第四季度以 5664 萬美元的價格收購了 Apellis Pharmaceuticals 的新頭寸。Great Lakes Advisors LLC 在第四季度以 1246.1 萬美元的價格購入了 Apellis Pharmaceuticals 的新頭寸。Mirae Asset Global Investments Co. Ltd.在第一季度購入了 Apellis Pharmaceuticals 股票 321.8 萬美元。最後，Bellevue Group AG 在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 3.5%。Bellevue Group AG 現在擁有公司股票 821800 股，價值 4919.3 萬美元，在上一季度購入了 27959 股。96.29% 的股份由機構投資者和對沖基金持有。</p>
<h2>分析師的升級和降級</h2>
<p>APLS 最近成為幾份研究報告的主題。富國銀行（Wells Fargo &amp; Company）將 Apellis Pharmaceuticals 的目標股價從 57.00 美元降至 48.00 美元，併為該公司設定了 “持平” 評級，日期為 2019 年 5 月 23 日。高盛集團（The Goldman Sachs Group）將 Apellis Pharmaceuticals 的目標股價從 66.00 美元上調至 74.00 美元，並在 2019 年 8 月 9 日的研究報告中為該股票設定了 “買入” 評級。派珀·桑德勒（Piper Sandler）在 2019 年 5 月 31 日的研究報告中開始對 Apellis Pharmaceuticals 進行覆蓋。他們為該公司設定了 “中性” 評級和 46.00 美元的目標股價。瑞銀集團（UBS Group）將 Apellis Pharmaceuticals 的目標股價從 85.00 美元降至 83.00 美元，並在 2019 年 8 月 9 日的研究報告中為該股票設定了 “買入” 評級。最後，摩根大通（JPMorgan Chase &amp; Co.）將 Apellis Pharmaceuticals 的目標股價從 72.00 美元降至 64.00 美元，並在 2019 年 8 月 13 日的研究報告中為該公司設定了 “超配” 評級。四位投資分析師對該股票進行了持有評級，十位給出了買入評級，一位給出了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “中等買入”，目標股價為 72.13 美元。</p>
<p><strong>查看我們對 APLS 的最新股票分析</strong></p>
<h2>Apellis Pharmaceuticals 的內部交易</h2>
<p>在其他 Apellis Pharmaceuticals 的消息中，董事 A. Sinclair Dunlop 於 2019 年 6 月 21 日的交易中出售了該公司的 37000 股股票。這些股票的平均價格為 39.24 美元，總交易額為 145.188 萬美元。交易後，該董事在公司中直接持有 136998 股股票，價值 537.58 萬美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接中查看。公司內部持有 6.80% 的股份。</p>
<h2>Apellis Pharmaceuticals 股票表現</h2>
<p>APLS 股票週五在午盤交易中上漲 0.18 美元，達到 38.90 美元。公司股票交易量為 636078 股，相比其平均交易量 1355396 股有所減少。該公司的資產負債比為 1.73，流動比率為 5.08，速動比率為 4.18。Apellis Pharmaceuticals, Inc.的 52 周最低價為 33.49 美元，52 周最高價為 73.80 美元。公司的 50 天移動平均價格為 37.94 美元，200 天移動平均價格為 46.71 美元。</p>
<p>Apellis Pharmaceuticals（NASDAQ:APLS - Get Free Report）於 2019 年 8 月 1 日發佈了最新的財報。該公司在本季度報告的每股收益（EPS）為-0.30 美元，高於分析師預期的-0.33 美元。本季度公司營收為 1.997 億美元，超過分析師預期的 1.9089 億美元。Apellis Pharmaceuticals 的淨資產回報率為-138.32%，淨利潤率為-52.99%。公司本季度的營收同比增長 110.2%。在去年同期的同一季度，公司每股虧損為-1.02 美元。分析師平均預計，Apellis Pharmaceuticals, Inc.今年將實現每股-1.28 美元的虧損。</p>
<h2>Apellis Pharmaceuticals 簡介（免費報告）</h2>
<p>Apellis Pharmaceuticals, Inc.是一家商業化階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療化合物，用於自身免疫性和炎症性疾病。該公司提供 EMPAVELI 用於治療夜間血紅蛋白尿、C3 腎小球病和免疫複合物膜增殖性腎小球腎炎，以及用於治療造血幹細胞移植相關性血栓性微血管病的藥物；SYFOVRE 用於治療由年齡相關性黃斑變性引起的地理性萎縮和地理性萎縮（GA）。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票，比 Apellis Pharmaceuticals 更好</li>
<li>在購買股票之前如何評估一家公司</li>
<li>不要忽視康寶食品：這是可能推動其股價的因素</li>
<li>投資優先股與普通股</li>
<li>比股票交易所滑坡——為什麼這可能是你的下一個大贏家</li>
<li>什麼是納斯達克證券交易所？</li>
<li>MarketBeat 周評 - 8/26 - 8/30</li>
</ul>
<p><strong>想知道其他對 Apellis Pharmaceuticals（納斯達克股票代碼：APLS - 免費報告）持有的對沖基金是什麼嗎？</strong> 訪問 HoldingsChannel.com 獲取最新的 13F 申報和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p>_這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速、最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</p>
<p>→ 曾預測拜登退出競選的前白宮顧問做出了驚人的新預測（來自 Paradigm Press）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5"/></p>
<h2>現在是否值得投資$1,000 購買 Apellis Pharmaceuticals？</h2>
<p>在考慮投資 Apellis Pharmaceuticals 之前，您可能想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高、表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在就買入的股票... 而 Apellis Pharmaceuticals 並不在名單上。</p>
<p>儘管 Apellis Pharmaceuticals 目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

APLS

<p>Lisanti Capital Growth LLC 在第二季度將其在 Apellis Pharmaceuticals（NASDAQ:APLS）的持股減少了 72.1％，賣出 64,325 股，保留 24,885 股。其他機構投資者也調整了他們的持股。分析師對 APLS 的意見不一，有四個持有評級，十個買入評級，共識目標價為 54.13 美元。內部交易包括董事 A. Sinclair Dunlop 出售了 37,000 股。APLS 股價週五上漲至 12.90 美元，52 周範圍為 5.49 美元至 18.80 美元，公司報告第二季度的每股收益為-0.30 美元，超過了預期</p>

<p>Lisanti Capital Growth LLC trimmed its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 72.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,885 shares of the company's stock after selling 64,325 shares during the quarter. Lisanti Capital Growth LLC's holdings in Apellis Pharmaceuticals were worth $955,000 at the end of the most recent reporting period.</p>
<ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><p>Lisanti Capital Growth LLC 在第二季度削減了其在 Apellis Pharmaceuticals, Inc.（NASDAQ:APLS - Free Report）的持股，根據該公司最新向 SEC 提交的 Form 13F 文件，該基金在本季度出售了 64325 股，持有公司股票 24885 股。Lisanti Capital Growth LLC 在最新報告期結束時持有的 Apellis Pharmaceuticals 股票價值 95.5 萬美元。</p>
<ul>
<li>Beam Therapeutics 因基因療法許可支付而大幅上漲</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently added to or reduced their stakes in APLS. Charles Schwab Investment Management Inc. grew its stake in shares of Apellis Pharmaceuticals by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 904,409 shares of the company's stock worth $54,138,000 after purchasing an additional 25,052 shares during the period. Norges Bank acquired a new position in Apellis Pharmaceuticals in the 4th quarter valued at $56,640,000. Great Lakes Advisors LLC purchased a new position in Apellis Pharmaceuticals in the 4th quarter valued at $12,461,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Apellis Pharmaceuticals in the first quarter worth about $3,218,000. Finally, Bellevue Group AG boosted its position in Apellis Pharmaceuticals by 3.5% during the fourth quarter. Bellevue Group AG now owns 821,800 shares of the company's stock worth $49,193,000 after acquiring an additional 27,959 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也增加或減少了對 APLS 的持股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第四季度增加了對 Apellis Pharmaceuticals 股票的持股比例，增長了 2.8%。查爾斯·施瓦布投資管理公司現在擁有公司股票 904409 股，價值 5413.8 萬美元，在此期間購買了 25052 股。挪威中央銀行在第四季度以 5664 萬美元的價格收購了 Apellis Pharmaceuticals 的新頭寸。Great Lakes Advisors LLC 在第四季度以 1246.1 萬美元的價格購入了 Apellis Pharmaceuticals 的新頭寸。Mirae Asset Global Investments Co. Ltd.在第一季度購入了 Apellis Pharmaceuticals 股票 321.8 萬美元。最後，Bellevue Group AG 在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 3.5%。Bellevue Group AG 現在擁有公司股票 821800 股，價值 4919.3 萬美元，在上一季度購入了 27959 股。96.29% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師的升級和降級</h2>
</div><p>APLS has been the subject of several recent research reports. Wells Fargo &amp; Company cut their price target on Apellis Pharmaceuticals from $57.00 to $48.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, May 23rd. The Goldman Sachs Group lifted their target price on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, August 9th. Piper Sandler initiated coverage on Apellis Pharmaceuticals in a research note on Friday, May 31st. They set a &#34;neutral&#34; rating and a $46.00 target price for the company. UBS Group decreased their target price on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, August 9th. Finally, JPMorgan Chase &amp; Co. dropped their target price on Apellis Pharmaceuticals from $72.00 to $64.00 and set an &#34;overweight&#34; rating for the company in a research report on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $72.13.</p>
<ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><p>APLS 最近成為幾份研究報告的主題。富國銀行（Wells Fargo &amp; Company）將 Apellis Pharmaceuticals 的目標股價從 57.00 美元降至 48.00 美元，併為該公司設定了 “持平” 評級，日期為 2019 年 5 月 23 日。高盛集團（The Goldman Sachs Group）將 Apellis Pharmaceuticals 的目標股價從 66.00 美元上調至 74.00 美元，並在 2019 年 8 月 9 日的研究報告中為該股票設定了 “買入” 評級。派珀·桑德勒（Piper Sandler）在 2019 年 5 月 31 日的研究報告中開始對 Apellis Pharmaceuticals 進行覆蓋。他們為該公司設定了 “中性” 評級和 46.00 美元的目標股價。瑞銀集團（UBS Group）將 Apellis Pharmaceuticals 的目標股價從 85.00 美元降至 83.00 美元，並在 2019 年 8 月 9 日的研究報告中為該股票設定了 “買入” 評級。最後，摩根大通（JPMorgan Chase &amp; Co.）將 Apellis Pharmaceuticals 的目標股價從 72.00 美元降至 64.00 美元，並在 2019 年 8 月 13 日的研究報告中為該公司設定了 “超配” 評級。四位投資分析師對該股票進行了持有評級，十位給出了買入評級，一位給出了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “中等買入”，目標股價為 72.13 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 APLS 的最新股票分析</strong></p>
</div><h2>Insider Transactions at Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 的內部交易</h2>
</div><p>In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at $5,375,801.52. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Corporate insiders own 6.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Apellis Pharmaceuticals 的消息中，董事 A. Sinclair Dunlop 於 2019 年 6 月 21 日的交易中出售了該公司的 37000 股股票。這些股票的平均價格為 39.24 美元，總交易額為 145.188 萬美元。交易後，該董事在公司中直接持有 136998 股股票，價值 537.58 萬美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接中查看。公司內部持有 6.80% 的股份。</p>
</div><h2>Apellis Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票表現</h2>
</div><p>Shares of APLS traded up $0.18 during mid-day trading on Friday, hitting $38.90. 636,078 shares of the company's stock were exchanged, compared to its average volume of 1,355,396. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $33.49 and a fifty-two week high of $73.80. The business's 50 day moving average is $37.94 and its two-hundred day moving average is $46.71.</p>
<div class="lb-trans"><p>APLS 股票週五在午盤交易中上漲 0.18 美元，達到 38.90 美元。公司股票交易量為 636078 股，相比其平均交易量 1355396 股有所減少。該公司的資產負債比為 1.73，流動比率為 5.08，速動比率為 4.18。Apellis Pharmaceuticals, Inc.的 52 周最低價為 33.49 美元，52 周最高價為 73.80 美元。公司的 50 天移動平均價格為 37.94 美元，200 天移動平均價格為 46.71 美元。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company's revenue for the quarter was up 110.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.28 earnings per share for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（NASDAQ:APLS - Get Free Report）於 2019 年 8 月 1 日發佈了最新的財報。該公司在本季度報告的每股收益（EPS）為-0.30 美元，高於分析師預期的-0.33 美元。本季度公司營收為 1.997 億美元，超過分析師預期的 1.9089 億美元。Apellis Pharmaceuticals 的淨資產回報率為-138.32%，淨利潤率為-52.99%。公司本季度的營收同比增長 110.2%。在去年同期的同一季度，公司每股虧損為-1.02 美元。分析師平均預計，Apellis Pharmaceuticals, Inc.今年將實現每股-1.28 美元的虧損。</p>
</div><h2>Apellis Pharmaceuticals Profile (Free Report)</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 簡介（免費報告）</h2>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家商業化階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療化合物，用於自身免疫性和炎症性疾病。該公司提供 EMPAVELI 用於治療夜間血紅蛋白尿、C3 腎小球病和免疫複合物膜增殖性腎小球腎炎，以及用於治療造血幹細胞移植相關性血栓性微血管病的藥物；SYFOVRE 用於治療由年齡相關性黃斑變性引起的地理性萎縮和地理性萎縮（GA）。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>MarketBeat Week in Review – 8/26 - 8/30</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票，比 Apellis Pharmaceuticals 更好</li>
<li>在購買股票之前如何評估一家公司</li>
<li>不要忽視康寶食品：這是可能推動其股價的因素</li>
<li>投資優先股與普通股</li>
<li>比股票交易所滑坡——為什麼這可能是你的下一個大贏家</li>
<li>什麼是納斯達克證券交易所？</li>
<li>MarketBeat 周評 - 8/26 - 8/30</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding APLS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 Apellis Pharmaceuticals（納斯達克股票代碼：APLS - 免費報告）持有的對沖基金是什麼嗎？</strong> 訪問 HoldingsChannel.com 獲取最新的 13F 申報和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p>_這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速、最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</p>
</div><p>→ Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 曾預測拜登退出競選的前白宮顧問做出了驚人的新預測（來自 Paradigm Press）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9339&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Apellis Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 購買 Apellis Pharmaceuticals？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Apellis Pharmaceuticals 之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高、表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在就買入的股票... 而 Apellis Pharmaceuticals 並不在名單上。</p>
</div><p>While Apellis Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Apellis Pharmaceuticals 目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Apellis Pharmaceuticals 公司（納斯達克股票代碼：APLS）的股份被 Lisanti Capital Growth LLC 出售